Burt Nabors

19.4k total citations · 1 hit paper
267 papers, 9.5k citations indexed

About

Burt Nabors is a scholar working on Genetics, Molecular Biology and Oncology. According to data from OpenAlex, Burt Nabors has authored 267 papers receiving a total of 9.5k indexed citations (citations by other indexed papers that have themselves been cited), including 156 papers in Genetics, 78 papers in Molecular Biology and 68 papers in Oncology. Recurrent topics in Burt Nabors's work include Glioma Diagnosis and Treatment (154 papers), Brain Metastases and Treatment (35 papers) and RNA Research and Splicing (23 papers). Burt Nabors is often cited by papers focused on Glioma Diagnosis and Treatment (154 papers), Brain Metastases and Treatment (35 papers) and RNA Research and Splicing (23 papers). Burt Nabors collaborates with scholars based in United States, Switzerland and Germany. Burt Nabors's co-authors include Peter H. King, G. Yancey Gillespie, Stuart A. Grossman, Tom Mikkelsen, David A. Reardon, Lualhati Harkins, Roger Stupp, Xiuhua Yang, Joy Fisher and Cheryl A. Palmer and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Burt Nabors

253 papers receiving 9.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Human cytomegalovirus infection and expression in human malignant glioma.

2002 559 citations G. Yancey Gillespie, Peter H. King et al. PubMed profile →

Peers

Countries citing papers authored by Burt Nabors

Since Specialization

Citations

This map shows the geographic impact of Burt Nabors's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Burt Nabors with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Burt Nabors more than expected).

Fields of papers citing papers by Burt Nabors

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Burt Nabors. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Burt Nabors. The network helps show where Burt Nabors may publish in the future.

Co-authorship network of co-authors of Burt Nabors

This figure shows the co-authorship network connecting the top 25 collaborators of Burt Nabors. A scholar is included among the top collaborators of Burt Nabors based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Burt Nabors. Burt Nabors is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Temozolomide chemotherapy for patients with newly diagnosed glioblastoma in the CENTRIC EORTC 26071-22072 and CORE trials: Does time of administration matter? 2025 ·Neuro-Oncology Practice ·Marjolein Geurts, (unknown), Franz Koenig, Burt Nabors, David A. Reardon, J. C. Tonn, Roger Stupp, Thierry Gorlia, Michael Weller, Matthias Preusser, (unknown)	1
2	Glioma grade and mortality in relation to sequence variation in the mitochondrial genome 2025 ·Cancer Genetics ·Noah C. Peeri, Jamie K. Teer, (unknown), Burt Nabors, Matthew D. Brooks, (unknown), Siôn L. Williams, Kathleen M. Egan	1
3	Proton Pump Inhibitor Use and Survival in Patients With Newly Diagnosed Glioblastoma 2025 ·JAMA Network Open ·Émilie Le Rhun, (unknown), Sara Erridge, David A. Reardon, Giuseppe Minniti, Patrick Roth, Wolfgang Wick, Burt Nabors, John H. Sampson, Warren Mason, Timothy F. Cloughesy, J.C. Reijneveld, Roger Stupp, Matthias Preusser, Thierry Gorlia, Michael Weller	0
4	INB-200: Fully enrolled phase 1 study of gene-modified autologous gamma-delta (γδ) T cells in patients with newly diagnosed glioblastoma multiforme (GBM) receiving maintenance temozolomide (TMZ). 2024 ·Journal of Clinical Oncology ·(unknown), Trishna Goswami, Lawrence S. Lamb, (unknown), (unknown), (unknown), Burt Nabors	2
5	Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade Glioma 2024 ·Clinical Cancer Research ·Karisa C. Schreck, Roy E. Strowd, Burt Nabors, Benjamin M. Ellingson, Michael Chang, Sze Kiat Tan, Zied Abdullaev, Rust Turakulov, Kenneth Aldape, (unknown), Serena Desideri, Joy Fisher, (unknown), (unknown), Michelle A. Rudek, Chetan Bettegowda, Stuart A. Grossman, Xiaobu Ye	7
6	Low-Dose Planned Glucarpidase Allows Safe Outpatient High-Dose Methotrexate Treatment for CNS Lymphoma 2024 ·JCO Oncology Practice ·Lauren Schaff, Dean Carlow, Ryan Schofield, (unknown), (unknown), (unknown), Anne S. Reiner, Katherine S. Panageas, Lisa M. DeAngelis, Ingo K. Mellinghoff, (unknown), Burt Nabors, Christian Grommes	1
7	Phase I and pharmacodynamic study of arsenic trioxide plus radiotherapy in patients with newly diagnosed glioblastoma 2024 ·Neuro-Oncology Advances ·Samuel Ryu, Xiaobu Ye, Jeffrey J. Olson, Tom Mikkelsen, Lev Bangiyev, Glenn J. Lesser, Tracy T. Batchelor, Burt Nabors, Serena Desideri, Tobias Walbert, Stuart A. Grossman	4
8	CTIM-13. PHASE I CLINICAL TRIAL OF ONCOLYTIC HSV-1 M032, A SECOND-GENERATION VIRUS ARMED TO EXPRESSED IL-12, FOR THE TREATMENT OF ADULT PATIENTS WITH RECURRENT OR PROGRESSIVE MALIGNANT GLIOMA 2023 ·Neuro-Oncology ·Dagoberto Estévez-Ordoñez, John P. Stein, (unknown), (unknown), (unknown), (unknown), Jennifer N. Clements, (unknown), Jianmei W. Leavenworth, Kristen Riley, Inmaculada Aban, Anna G. Sorace, (unknown), Burt Nabors, James M. Markert	7
9	P11.46.A ACTION: A RANDOMIZED PHASE 3 STUDY OF DORDAVIPRONE (ONC201) IN PATIENTS WITH NEWLY DIAGNOSED H3 K27M-MUTANT DIFFUSE GLIOMA 2023 ·Neuro-Oncology ·Isabel Arrillaga‐Romany, Andrew B. Lassman, Susan L. McGovern, Sabine Mueller, Burt Nabors, Martin J. van den Bent, Michael A. Vogelbaum, (unknown), Allen S. Melemed, Rohinton S. Tarapore, Patrick Y. Wen, (unknown)	0
10	Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma 2022 ·Neuro-Oncology ·Émilie Le Rhun, Felix Boakye Oppong, (unknown), Roger Stupp, Burt Nabors, Olivier Chinot, Wolfgang Wick, Matthias Preusser, Thierry Gorlia, Michael Weller	14
11	Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement 2021 ·Clinical Cancer Research ·Stephen Bagley, Shawn Kothari, Rifaquat Rahman, Eudocia Q. Lee, Gavin P. Dunn, Evanthia Galanis, Susan M. Chang, Burt Nabors, Manmeet S. Ahluwalia, Roger Stupp, Minesh P. Mehta, David A. Reardon, Stuart A. Grossman, Erik P. Sulman, John H. Sampson, Simon Khagi, Michael Weller, Timothy F. Cloughesy, Patrick Y. Wen, Mustafa Khasraw	104
12	Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors 2021 ·Cancer Research ·Natalia Filippova, Xiuhua Yang, Subramaniam Ananthan, (unknown), Vibha Pathak, (unknown), Rakesh H. Vekariya, Sixue Zhang, Edward Ofori, (unknown), (unknown), David K. Crossman, Michael R. Crowley, Peter H. King, James A. Mobley, Burt Nabors	27
13	MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials 2018 ·Clinical Cancer Research ·Monika E. Hegi, (unknown), Thierry Gorlia, Roger Stupp, Mark R. Gilbert, Olivier Chinot, Burt Nabors, Greg Jones, Wim Van Criekinge, Josef Straub, Michael Weller	90
14	Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma 2018 ·Clinical Cancer Research ·Jaishri O. Blakeley, Stuart A. Grossman, S. Andrew, Tom Mikkelsen, Myrna R. Rosenfeld, Manmeet S. Ahluwalia, Burt Nabors, April F. Eichler, (unknown), Serena Desideri, Xiaobu Ye	18
15	Associations of anticoagulant use with outcome in newly diagnosed glioblastoma 2018 ·European Journal of Cancer ·Émilie Le Rhun, (unknown), Roger Stupp, Olivier Chinot, Burt Nabors, Timothy F. Cloughesy, David A. Reardon, Wolfgang Wick, Thierry Gorlia, Michael Weller	10
16	Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma 2016 ·PubMed ·Daxa Patel, Paul M. Foreman, Burt Nabors, Kristen Riley, G. Yancey Gillespie, James M. Markert	122
17	A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma 2013 ·Clinical Cancer Research ·David A. Reardon, Morris D. Groves, Patrick Y. Wen, Burt Nabors, Tom Mikkelsen, Steve Rosenfeld, Jeffrey J. Raizer, Jorge Barriuso, Roger E. McLendon, A. Benjamin Suttle, Bo Ma, C. Martin Curtis, Mohammed M. Dar, Johann S. de Bono	91
18	The RNA-Binding Protein HuR Promotes Glioma Growth and Treatment Resistance 2011 ·Molecular Cancer Research ·Natalia Filippova, Xiuhua Yang, Yimin Wang, G. Yancey Gillespie, (unknown), Peter H. King, Crystal G. Wheeler, Burt Nabors	126
19	Rationally Designed Pharmacogenomic Treatment Using Concurrent Capecitabine and Radiotherapy for Glioblastoma; Gene Expression Profiles Associated with Outcome 2010 ·Clinical Cancer Research ·Jessica M. Grunda, John B. Fiveash, Cheryl A. Palmer, Alan Cantor, Hassan M. Fathallah‐Shaykh, Burt Nabors, Martin R. Johnson	25
20	Loss of Protein Inhibitors of Activated STAT-3 Expression in Glioblastoma Multiforme Tumors: Implications for STAT-3 Activation and Gene Expression 2008 ·Clinical Cancer Research ·Emily C. Brantley, Burt Nabors, G. Yancey Gillespie, Youn‐Hee Choi, Cheryl A. Palmer, Keith Harrison, Kevin Roarty, Etty Benveniste	157

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact